

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2018

DESPATCHED ON 30TH NOVEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B7, -; Cw7, -; DR4, DR15; DQ6, DQ8

| | | | | | Summary of Results | | | | | | | | | | | | | |
|--|----------------|-------------------|-------------------|--|--------------------|-----------------|-----------------|-----------------|-----------------|---------------------|-----------------|-----------------|---------------------|-----------------|-----------------|-----------------|---|--|
| | | | | | PBL | | | | T-Cells | | | | B-Cells | | | | | |
| | | | | | 5 | 7 | 6 | 6 | 30 | 29 | 30 | 29 | 29 | 28 | 30 | 28 | | |
| | | | | | 1 | 1 | 0 | 1 | 4 | 11 | 1 | 7 | 19 | 23 | 4 | 25 | | |
| | | | | | 4 | 6 | 6 | 5 | 26 | 18 | 29 | 22 | 10 | 5 | 26 | 3 | | |
| | | | | | 2 | 1 | 2 | 2 | 4 | 5 | 4 | 5 | 6 | 7 | 5 | 7 | | |
| | | | | | % Positive | 20.0% | 14.3% | 0.0% | 16.7% | 13.3% | 37.9% | 3.3% | 24.1% | 65.5% | 82.1% | 13.3% | 89.3% | |
| | | | | | % Negative | 80.0% | 85.7% | 100.0% | 83.3% | 86.7% | 62.1% | 96.7% | 75.9% | 34.5% | 17.9% | 86.7% | 10.7% | |
| | | | | | Negative | Negative | Negative | Negative | Negative | Not Assessed | Negative | Negative | Not Assessed | Positive | Negative | Positive | | |
| | | | | | DR3 | Multi B7 B27 | Cw2 | B7 | DR3 | Multi B7 B27 | Cw2 | B7 | DR3 | Multi B7 B27 | Cw2 | B7 | | |
| HLA Antibody Specificity (Defined By CDC) | | | | | | | | | | | | | | | | | | |
| | | | | | Without DTT | | | | Without DTT | | | | Without DTT | | | | | |
| Lab No. | PBL Assessment | T Cell Assessment | B Cell Assessment | | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Comments | |
| 9 | YES | YES | YES | | Negative | Negative | Negative | NT | Negative | Negative | Negative | NT | Negative | Negative | Negative | NT | Poor cell viability and inconclusive results for serum 4 for PBL, T cell and B cell | |
| 11 | YES | YES | YES | | Negative | Negative | Negative | Negative | NT | NT | NT | NT | NT | NT | NT | NT | Delay in supply of class II Dynabeads therefore reserved for urgent use. T cell yield and viability low. | |
| 12 | YES | YES | YES | | NT | NT | NT | NT | Negative | Positive | Negative | Positive | Positive | Positive | Negative | Positive | PBL not tested due to insufficient material. Reaction strength entered only if above negative control | |
| 20 | YES | YES | YES | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 23 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 24 | | YES | YES | | | | | | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | | |
| 25 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Positive | | |
| 28 | | YES | YES | | | | | | NT | NT | NT | NT | NT | NT | NT | NT | very poor viability for both T and B cells. Low cell numbers. | |
| 34 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | | |
| 38 | YES | YES | YES | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | | |
| 39 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Positive | | |
| 41 | | YES | YES | | | | | | Positive | Positive | Negative | Positive | Positive | Positive | Negative | Positive | | |
| 42 | YES | YES | YES | | Positive | Positive | Negative | Positive | | | | | Positive | Positive | Negative | Positive | | |
| 45 | | YES | YES | | | | | | Negative | Positive | Negative | Positive | Positive | Positive | Negative | Positive | | |
| 51 | | YES | YES | | | | | | Positive | Positive | Negative | Positive | Positive | Positive | Positive | Positive | The controls in the DTT wells did not work on 2 occasions and so we have no viable results to report for the with DTT section | |
| 54 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | NT | NT | NT | NT | B cell viability was poor, hence results would not be reported in a clinical situation. | |
| 58 | | YES | YES | | | | | | Negative | Positive | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 101 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Positive | | |
| 114 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Positive | | |
| 116 | | YES | YES | | | | | | Positive | Positive | Negative | Positive | Positive | Positive | Negative | Positive | | |
| 117 | YES | | | | NT | Negative | NT | Negative | | | | | | | | | Sera 1 and 3 were not tested as there weren't enough cells. | |
| 136 | | YES | | | | | | | Negative | Positive | Negative | Negative | | | | | | |
| 145 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | |
| 149 | YES | | | | Negative | Negative | Negative | Negative | | | | | Negative | Negative | Negative | Negative | | |
| 162 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 181 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | NT | NT | Negative | Positive | | |
| 186 | | YES | YES | | | | | | Negative | Positive | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 204 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 206 | | YES | YES | | | | | | Negative | Positive | Negative | Negative | Negative | Positive | Negative | Positive | Low cell count | |
| 223 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 227 | | YES | YES | | | | | | Negative | NT | Negative | Negative | Negative | NT | Negative | NT | Low cell count | |
| 268 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Negative | | |
| 284 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 297 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Positive | | |
| 311 | | YES | YES | | | | | | NT | NT | NT | NT | NT | NT | NT | NT | very poor viability for this sample | |
| 315 | | YES | YES | | | | | | NT | NT | NT | NT | NT | NT | NT | NT | Uninterpretable due to IgM control positive with DTT | |
| 351 | | YES | YES | | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | NT due to low cell viability | |
| 406 | | YES | YES | | | | | | NT | NT | NT | NT | NT | NT | NT | NT | No results returned | |
| 411 | | YES | YES | | | | | | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive | | |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2018

DESPATCHED ON 30TH NOVEMBER 2018

| Lab No. | PBL without DTT | | | | T-cell without DTT | | | | B-cell without DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 9 | 0 | 0 | 0 | NT | 0 | 0 | 0 | NT | 0 | 0 | 0 | NT | 80 | 80 | 60 |
| 11 | - | - | - | - | NT | NT | NT | NT | NT | NT | NT | NT | 90 | - | - |
| 12 | NT | NT | NT | NT | - | 40% | 15% | 40% | 100% | 80% | - | 100% | - | 80 | 95 |
| 20 | 1 | 1 | 1 | 1 | | | | | 8 | 6 | 1 | 6 | 95 | - | 85 |
| 23 | | | | | 1 | 1 | 1 | 1 | 4 | 4 | 1 | 4 | - | 90 | 80 |
| 24 | | | | | 20 | 30 | 20 | 30 | 30 | 40 | 20 | 40 | - | 90 | 90 |
| 25 | | | | | 1 | 2 | 1 | 1 | 4 | 6 | 4 | 8 | - | 100 | 100 |
| 28 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | 65 | 65 |
| 34 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | - | 95 | 80 |
| 38 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 98 | 98 | 80 |
| 39 | | | | | - | - | - | - | 8 | 8 | 2 | 8 | - | 99 | 90 |
| 41 | | | | | 20 | 15-20 | 5-10 | 30 | 35 | 25-30 | 5-10 | 50 | - | 95 | 90 |
| 42 | 20-40% | 10-20% | <10% | 10-20% | | | | | 60-80% | 40-60% | <10% | 80-100% | 95 | - | 95 |
| 45 | | | | | 1-2 | 6 | 1 | 6 | 6 | 6 | 1 | 8 | - | 85 | 85 |
| 51 | | | | | 6 | 6 | 0 | 6 | 8 | 8 | 4 | 8 | - | - | - |
| 54 | | | | | 11-20 | 11-20 | <5 | <5 | NT | NT | NT | NT | - | 95 | <80% |
| 58 | | | | | 5% | 40% | 5% | 10% | 95% | 90% | 15% | 90% | - | 95 | 90 |
| 101 | | | | | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 6 | - | - | - |
| 114 | | | | | 1 | 2 | 1 | 1 | 2 | 4 | 1 | 4 | - | - | - |
| 116 | | | | | 1-6 | 1-4 | 1 | 1-2 | 1-8 | 2-6 | 1-2 | 1-6 | - | 95 | 90 |
| 117 | NT | 1 | NT | 1 | | | | | | | | | 83 | - | - |
| 136 | | | | | 1 | 4 | 1 | 1 | | | | | - | 99 | 85 |
| 145 | | | | | - | - | - | - | - | - | - | - | - | 100 | 100 |
| 149 | - | - | - | - | | | | | | | | | 87 | - | - |
| 162 | | | | | - | - | - | - | 2/4 1:1 | 4/6 1:1 | - | 2/4 1:4 | - | 100 | 100 |
| 181 | | | | | 1 | 1 | 1 | 1 | NT | NT | 2 | 8 | - | 100 | 85 |
| 186 | | | | | 0 | 2 | 0 | 0 | 2 | 4 | 0 | 2 | - | 99 | 99 |
| 204 | | | | | 1 | 1 | 1 | 1 | 4 | 6 | 2 | 6 | - | - | - |
| 206 | | | | | 0 | 4 | 0 | 0 | 0 | 6 | 0 | 6 | - | 80 | 85 |
| 223 | | | | | 1 | 2-4 | 1 | 1 | 8 | 6-8 | 1 | 8 | - | 100 | 90 |
| 227 | | | | | - | NT | - | - | - | NT | - | NT | - | 98 | 98 |
| 268 | | | | | 1 | 1 | 1 | 1 | 4 | 4 | 1 | 1 | - | 80 | 90 |
| 284 | | | | | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 8 | - | 95 | 90 |
| 297 | | | | | 1 | 1 | 1 | 1 | 8 | 6 | 1 | 8 | - | 80 | 60 |
| 311 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | - | - |
| 315 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 80 | 80 |
| 351 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | | | |
| 406 | | | | | | | | | | | | | | | |
| 411 | | | | | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | - | 65 | 60 |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2018

DESPATCHED ON 30TH NOVEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B7, -; Cw7, -; DR4, DR15; DQ6, DQ8

| | | | | Summary of Results | | | | | | | | | | | | | | | |
|--|----------------|-------------------|-------------------|--------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|--|-----|----|--|
| | | | | PBL | | | | T-Cells | | | | B-Cells | | | | | | | |
| | | | | 6 | 6 | 6 | 5 | 24 | 22 | 24 | 23 | 25 | 24 | 26 | 23 | | | | |
| | | | | 0 | 0 | 0 | 0 | 2 | 5 | 1 | 3 | 3 | 5 | 1 | 3 | | | | |
| | | | | 6 | 6 | 6 | 5 | 22 | 17 | 23 | 20 | 22 | 19 | 25 | 20 | | | | |
| | | | | 1 | 1 | 1 | 2 | 7 | 9 | 7 | 8 | 8 | 9 | 7 | 10 | | | | |
| | | | | 0.0% | 0.0% | 0.0% | 0.0% | 8.3% | 22.7% | 4.2% | 13.0% | 12.0% | 20.8% | 3.8% | 13.0% | | | | |
| | | | | 100.0% | 100.0% | 100.0% | 100.0% | 91.7% | 77.3% | 95.8% | 87.0% | 88.0% | 79.2% | 96.2% | 87.0% | | | | |
| Consensus | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| HLA Antibody Specificity (Defined By CDC) | | | | DR3 | Multi B7 | B27 | Cw2 | B7 | DR3 | Multi B7 | B27 | Cw2 | B7 | DR3 | Multi B7 | B27 | Cw2 | B7 | |
| Lab No. | PBL Assessment | T Cell Assessment | B Cell Assessment | With DTT | | | | With DTT | | | | With DTT | | | | Comments | | | |
| | | | | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | | | | |
| 9 | YES | YES | YES | Negative | Negative | Negative | NT | Negative | NT | Negative | NT | Negative | Negative | Negative | NT | Poor B cell viability and inconclusive results for serum 4 for PBL, T cell and B cell. Delay in supply of class II Dynabeads therefore reserved for urgent use. T cell yield and viability low. | | | |
| 11 | YES | YES | YES | Negative | Negative | Negative | Negative | NT | NT | NT | NT | NT | NT | NT | NT | | | | |
| 12 | YES | YES | YES | NT | NT | NT | NT | Negative | Positive | Negative | Positive | Negative | Negative | Negative | Negative | PBL not tested due to insufficient material. Reaction strength entered only if above negative control. Delay in sample receipt | | | |
| 15 | | YES | YES | | | | | NT | NT | NT | NT | NT | NT | NT | NT | | | | |
| 20 | YES | | YES | Negative | Negative | Negative | Negative | NT | NT | NT | NT | Negative | Positive | Negative | Negative | T cells with DTT could not be reported as an invalid result was obtained due to poor viability of the cells. Serum 4 B cells with DTT could not be reported due to poor viability of cells. | | | |
| 24 | | YES | YES | | | | | NT | NT | NT | NT | Negative | Negative | Negative | Negative | | | | |
| 25 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Very poor viability for both T and B cells. Low cell numbers. | | | |
| 28 | | YES | YES | | | | | NT | NT | NT | NT | NT | NT | NT | NT | | | | |
| 34 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | The controls in the DTT wells did not work on 2 occasions and so we have no viable results to report for the with DTT section B cell viability was poor, hence results would not be reported in a clinical situation. | | | |
| 38 | YES | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 39 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Low cell count | | | |
| 41 | | YES | YES | | | | | Positive | Positive | Negative | Positive | Positive | Positive | Negative | Positive | | | | |
| 42 | YES | | YES | Negative | Negative | Negative | Negative | | | | | Negative | Negative | Negative | Negative | Low cell count | | | |
| 45 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 51 | | YES | YES | | | | | NT | NT | NT | NT | NT | NT | NT | NT | Very poor viability for this sample Uninterpretable due to IgM control positive with DTT | | | |
| 54 | | YES | YES | | | | | Negative | Negative | Negative | Negative | NT | NT | NT | NT | | | | |
| 58 | | YES | YES | | | | | Negative | Positive | Negative | Negative | Negative | Positive | Negative | Negative | NT due to low cell viability | | | |
| 101 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 114 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | No results returned | | | |
| 116 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 149 | YES | | YES | Negative | Negative | Negative | Negative | | | | | | | | | No results returned | | | |
| 162 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 181 | | YES | YES | | | | | Negative | Negative | Negative | Negative | NT | NT | Negative | Negative | No results returned | | | |
| 186 | | YES | YES | | | | | Negative | Positive | Negative | Negative | Positive | Positive | Negative | Positive | | | | |
| 204 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | No results returned | | | |
| 206 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 227 | | YES | YES | | | | | Negative | NT | Negative | Negative | Negative | NT | Negative | NT | No results returned | | | |
| 268 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 284 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | No results returned | | | |
| 297 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 311 | | YES | YES | | | | | NT | NT | NT | NT | NT | NT | NT | NT | No results returned | | | |
| 315 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | | | |
| 351 | | YES | YES | | | | | NT | NT | NT | NT | NT | NT | NT | NT | No results returned | | | |
| 406 | | YES | YES | | | | | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive | | | | |
| 411 | | YES | YES | | | | | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive | | | | |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2018

DESPATCHED ON 30TH NOVEMBER 2018

| Lab No. | PBL with DTT | | | | T-cell with DTT | | | | B-cell with DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 9 | 0 | 0 | 0 | NT | 0 | NT | 0 | NT | 0 | 0 | 0 | NT | 80 | 80 | 60 |
| 11 | - | - | - | - | NT | NT | NT | NT | NT | NT | NT | NT | 90 | - | - |
| 12 | NT | NT | NT | NT | - | 40% | - | 30% | 15% | 15% | - | - | - | 80 | 95 |
| 15 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | - | - |
| 20 | 1 | 1 | 1 | 1 | | | | | 1 | 2 | 1 | 1 | 95 | - | 85 |
| 24 | | | | | NT | NT | NT | NT | 20 | 20 | 20 | NT | - | 90 | 90 |
| 25 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 100 | 100 |
| 28 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | 65 | 65 |
| 34 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 95 | 80 |
| 38 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 98 | 98 | 80 |
| 39 | | | | | - | - | - | - | - | - | - | - | - | 99 | 90 |
| 41 | | | | | 20 | 25-30 | 15 | 40 | 50 | 30-40 | 15 | 70 | - | 95 | 90 |
| 42 | <10% | <10% | <10% | <10% | | | | | <10% | <10% | <10% | <10% | 95 | - | 95 |
| 45 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 85 | 85 |
| 51 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | - | - |
| 54 | | | | | <5 | <5 | <5 | <5 | NT | NT | NT | NT | - | 95 | <80 |
| 58 | | | | | 5% | 50% | 5% | 5% | 10% | 50% | 10% | 10% | - | 95 | 90 |
| 101 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - |
| 114 | | | | | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | - | - | - |
| 116 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 95 | 90 |
| 149 | - | - | - | - | | | | | | | | | 87 | - | - |
| 162 | | | | | - | - | - | - | - | - | - | - | - | 100 | 100 |
| 181 | | | | | 1 | 1 | 1 | 1 | NT | NT | 2 | 2 | - | 100 | 85 |
| 186 | | | | | 0 | 2 | 0 | 0 | 2 | 2 | 0 | 2 | - | 99 | 99 |
| 204 | | | | | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | - | - | - |
| 206 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 80 | 85 |
| 227 | | | | | - | NT | - | - | - | NT | - | NT | - | 98 | 98 |
| 268 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 80 | 90 |
| 284 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 95 | 90 |
| 297 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 80 | 60 |
| 311 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | - | - |
| 315 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 80 | 80 |
| 351 | | | | | NT | NT | NT | NT | NT | NT | NT | NT | - | - | - |
| 406 | | | | | | | | | | | | | | | |
| 411 | | | | | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | - | 65 | 60 |